The monoclonal antibody MIB-1 reacts with the same antigen as Ki67 antigen giving an estimate of growth fraction. The authors investigated whether MIB-1 staining, using semiquantative analysis and DNA ploidy study, could be a prognostic indicator of recurrence in endometrial carcinoma.

The tumors from 45 consecutive patients receiving primary surgical therapy for endometrial carcinoma were evaluated with MIB-1 monoclonal antibody and DNA ploidy status. Growth fraction was quantified by counting stained nucleus in HPF. DNA ploidy study was evaluated by flow cytometry. The patients were followed for 5 years and their charts were reviwed to determine recurrence, stage,and grade.

MIB-1 staing was significantly elevated in histologic high grade (grade II and III) as opposed to low grade(grade I) carcinoma (P=0.038). Aneuploidy was significantly increased incidence in advaned stage (stage III and IV) as opposed to early stage(stage I and II) (P=0.017). MIB-1 staing and aneuploidy were associated with increased incidence of recurrence within 5 years of diagnosis, but not statistically significance.

In this series of 45 patients with endometrial carcinoma. MIB-1 monoclonal antibody staining and aneuploidy to be a prognostic indicators of recurrence.